Phase II trial of Belagenpumatucel-L, a TGF-Β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients

Cancer Gene Therapy

Volumn 16, Issue 8, 2009, Pages 620-624

  Nemunaitis, J ^a,b,c   Nemunaitis, M ^b   Senzer, N ^a,b,c   Snitz, P ^a   Bedell, C ^a   Kumar, P ^d   Pappen, B ^d   Maples, P B ^d   Shawler, D ^e   Fakhrai, H ^e  

^a Mary Crowley Cancer Research Centers   (United States)

^b TEXAS ONCOLOGY   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d GRADALIS INC   (United States)

^e NovaRx Corporation   (United States)

Author keywords

TGF 2 Antisense; Belagenpumatucel L; vaccine; NSCLC

Indexed keywords

BELAGENPUMATUCEL L; TUMOR VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTISENSE THERAPY; ARTICLE; CANCER IMMUNIZATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; LUNG NON SMALL CELL CANCER; MALE; OPTIMAL DRUG DOSE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TUMOR CELL; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DNA, ANTISENSE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE THERAPY; HUMANS; INJECTIONS, INTRADERMAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; TRANSFORMING GROWTH FACTOR BETA2; TUMOR CELLS, CULTURED;

EID: 67651091694     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.15     Document Type: Article

References (36)

1. Sporn MB, Roberts AB, Wakefield LM, Assoian RK.d Transforming growth factor-beta: biological function and chemical structure. Science 1986; 233: 532-534.
2. Massague J. The TGF-beta family of growth and differentiation factors. Cell 1987; 49: 437-438.
3. Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I et al. Immunosuppression and transforming growth factorbeta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 1989; 143: 3222-3229.
4. Border WA, Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 1992; 90: 1-7.
5. Jakowlew SB, Mathias A, Chung P, Moody TW. Expression of transforming growth factor beta ligand and receptor messenger RNAs in lung cancer cell lines. Cell Growth Differ 1995; 6: 465-476.
6. Constam DB, Philipp J, Malipiero UV, ten Dijke P, Schachner M, Fontana A. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol 1992; 148: 1404-1410.
7. Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS. Plasma transforming growth factor-beta1 level before radiotherapycorrelates with long term outcome of patients with lung carcinoma. Cancer 1999; 86: 1712-1719.
8. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986; 136: 3916-3920.
9. Kasid A, Bell GI, Director EP. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J Immunol 1988; 141: 690-698.
10. Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages bytransforming growth factor-beta. Nature 1988; 334: 260-262.
11. Hirte H, Clark DA. Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor. Cancer Immunol Immunother 1991; 32: 296-302.
12. Naganuma H, Sasaki A, Satoh E, Nagasaka M, Nakano S, Isoe S et al. Transforming growth factor-beta inhibits interferon-gamma secretion byly mphokine-activated killer cells stimulated with tumor cells. Neurol Med Chir (Tokyo) 1996; 36: 789-795.
13. Ruffini PA, Rivoltini L, Silvani A, Boiardi A, Parmiani G. Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol Immunother 1993; 36: 409-416.
14. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006; 24: 4721-4730.
15. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000; 342: 525-533.
16. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
17. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL et al. Eradication of established intracranial rat gliomas bytransforming growth factor beta antisense gene therapy. Proc Natl Acad SciUSA 1996; 93: 2909-2914.
18. Salgaller ML. The development of immunotherapies for non-small cell lung cancer. Expert Opin Biol Ther 2002; 2: 265-278.
19. Ratto GB, Zino P, Mirabelli S, Minuti P, Aquilina R, Fantino G et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapyin the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer 1996; 78: 244-251.
20. Lissoni P, Meregalli S, Fossati V, Paolorossi F, Barni S, Tancini G et al. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapywith cisplatin and etoposide as first-line therapyfor advanced non-small cell lung cancer. Tumori 1994; 80: 464-467.
21. Ratto GB, Cafferata MA, Scolaro T, Bruzzi P, Alloisio A, Costa R et al. Phase II study of combined immunotherapy, chemotherapy, and radiotherapy in the postoperative treatment of advanced non-small-cell lung cancer. J Immunother 2000; 23: 161-167.
22. Nemunaitis J, Sterman D, Jablons D, Smith II JW, Fox B, Maples P et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in nonsmall-cell lung cancer. J Natl Cancer Inst 2004; 96: 326-331.
23. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunityin some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 2003; 21: 624-630.
24. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor byadenoviral-mediated gene transfer augments antitumor immunityin patients with metastatic melanoma. J Clin Oncol 2003; 21: 3343-3350.
25. Morse MA. Technologyevaluation: BLP-25, Biomira Inc. Curr Opin Mol Ther 2001; 3: 102-105.
26. Nemunaitis J. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev Vaccines 2005; 4: 259-274.
27. Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 2002; 8: 2073-2084.
28. Soria JC, Gauthier LR, Raymond E, Granotier C, Morat L, Armand JP et al. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients. Clin Cancer Res 1999; 5: 971-975.
29. Ruddon RW. Cancer Biology, 3rd edn. Oxford University Press, 1995; 318-340.
30. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthysubjects or patients with nonmalignant diseases. Clin Cancer Res 2004; 10: 6897-6904.
31. Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with colorectal cancer. J Clin Oncol 2008; 26: 3213-3221.
32. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E et al. Circulating tumor cell unmber and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007; 13: 7053-7058.
33. Katoh M, Neumaier M, Nezam R, Izbicki JR, Schumacher U. Correlation of circulating tumor cells with tumor size and metastatic load in a spontaneous lung metastasis model. Anticancer Res 2004; 24: 1421-1425.
34. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC et al. Circulating tumor cells versus imagingpredicting overall survival in metastatic breast cancer. Clin Cancer Res 2006; 12: 6403-6409.
35. Heiser A, COleman D, Dannull J, Yancey D, Maurice MA, Lallas CD et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL response against metastatic prostate tumors. J Clin Inv 2002; 109: 409-417.
36. Stojadinovic A, Mittendorf EA, Holmes JP, Amin A, Hueman MT, Ponniah S et al. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapyfor breast cancer: a pilot study. Ann Surg 2007; 14: 3359-3368.